In short
Clinical trials investigating "MAGNESIUM CARBONATE HEAVY" are studying treatment for people with dyspepsia, also called indigestion. The trials aim to compare symptom improvement and help show whether a shorter treatment plan works as well as a longer one. They focus on patients with unexplained dyspepsia.
Key points
- Clinical trials investigating "MAGNESIUM CARBONATE HEAVY" are focused on dyspepsia, also known as indigestion. The study is a Phase 3 randomized, non-inferiority trial with 128 planned participants. It compares 7 days versus 4 weeks of treatment and looks at changes in the modified Glasgow Dyspepsia Severity Score. The target population is people with unexplained dyspepsia. The trial is authorised and is designed to see whether the shorter treatment plan performs similarly to the longer one.
Trial overview
This clinical trial is studying MAGNESIUM CARBONATE HEAVY in people with dyspepsia, which means indigestion. The study is titled as a randomized, non-inferiority trial and is authorised.
The trial compares 7-day treatment with 4-week treatment in patients with unexplained dyspepsia. The main question is whether the shorter treatment plan works well enough compared with the longer plan.
Study design and phase
This is an interventional study, which means the researchers give a treatment and then measure the results. It is in Phase 3, a later stage of research that usually checks how well a treatment works in a larger group of people.
The trial plans to enroll 128 participants. It is also described as randomized, which means people are assigned to a treatment group by chance.
Who can join the study
The target population is patients with unexplained dyspepsia. The source data does not give more detailed inclusion or exclusion rules, so the main known requirement is the condition being studied.
Because the trial focuses on unexplained dyspepsia, it is meant for people whose indigestion symptoms are being evaluated in this study setting.
What is being measured
The main outcome is the change in the modified Glasgow Dyspepsia Severity Score (GDSS). This score is used to measure how severe dyspepsia symptoms are, so the study can track whether symptoms improve over time.
The trial compares the change from Week 1, which covers Days 1 to 7, to Weeks 2 to 4, which cover Days 8 to 28. The treatment effect is the difference between the two study groups, and the non-inferiority margin is 2 points.
Why this trial matters
This study is looking at whether a shorter treatment course can be close enough to a longer course for symptom control in dyspepsia. If the shorter plan performs well, it may help answer an important practical question for patients and researchers about treatment length.
Because the trial is focused on symptoms rather than a disease cure, its main value is in understanding how treatment duration affects patient-reported discomfort.